Aim: To explore the feasibility of the electronic assessment of potentially inappropriate medication (PIM) criteria in a large administrative database and to explore the validity of the cardiovascular subset of PIM criteria, by studying the association with relevant outcome. Method: A cohort study using administrative data from Stockholm County, Sweden (VAL database). Eligible for inclusion were community-dwelling older people (≥65 years), alive in Stockholm County on 31 December 2015. We applied PIM criteria pertaining to the cardiovascular medication group (first-level ATC C group), and we assessed the association between PIM use and mortality and hospitalisation. Results: Patients' (n = 315 120) mean age was 74.0 years (range 65-114), and 54.7% were women. There were 111 cardiovascular PIM criteria in the repository, from which 44 were not registered or prescribed in our population. We excluded another 43 requiring information not available in the database, or duplicates, resulting in 24 applicable criteria. The prevalence of polypharmacy (≥ five medications) was 25.5% and the prevalence of at least one PIM use was 8.3%, including 2.8% underuse and 5.3% misuse. Patients with intake of ≥10 medications had 38% increased mortality risk compared to those with 0-4 medications. Unplanned hospitalisation and emergency department visits were positively associated with underuse (12% and 25%, respectively) and misuse (13% and 12%, respectively). Conclusion: It was feasible to select a subset of cardiovascular PIM criteria originating from different PIM lists and to apply this subset in an administrative database. Additionally, by applying this subset, we showed significant associations with clinical outcome.
| INTRODUCTION
Older adults are more sensitive to the effects of medications because of age-related changes in pharmacokinetics and pharmacodynamics. 1 Prescribing in the older population can be potentially inappropriate if the benefits are outweighed by the harms. 2 High medication use and polypharmacy (defined as the daily intake of five medications or more) 3 increase the risk of inappropriate prescribing, resulting in increased risk of adverse drug events, morbidity, utilisation of healthcare resources and mortality.
Lists of potentially inappropriate medication (PIM lists) have been developed to help and guide clinicians in their assessment of inappropriate prescribing in older adults. 1, 2, [6] [7] [8] [9] [10] These criteria can be divided into explicit and implicit criteria. Implicit criteria are judgement-based, patient-specific and require a high level of skill from the assessor (eg the Medication Appropriateness Index (MAI), 11 ACOVE Quality Indicator Set 12 ). Explicit criteria are not judgement-based, but are rather formulated as an algorithm (eg Beers' lists, 2 STOPP/START, 7 EU(7)-PIM list, 8 PRISCUS, 10 NORGEP 9 ). PIM lists have been used to assess the quality of care in different healthcare settings as well as pharmacotherapy in individual patients. Application of these tools in clinical practice is often limited, mainly because of lack of adaptability to national drug markets, lack of suitability for automated electronic assessment and limited access to high-quality medical information in electronic health records. 13 Recent studies
and an expert meeting of the European Science Foundation recommended the construction of a repository of PIM lists and the implementation of a computerised monitoring system of PIMs, with regular personalised feedback to the responsible prescribers. 13, 14 Therefore, we created an European repository of PIM criteria 15 by combining criteria from the last versions of three PIM lists: EU(7)-PIM list, 8 STOPP/START 2014 7 and BEERS 2015. 2 These criteria are suitable for use in European countries and have been applied in several studies. [16] [17] [18] [19] [20] All the criteria of these three lists were integrated in the repository, and we created a Webbased tool for researchers to facilitate the selection of criteria for electronic assessment in specific studies. We called this tool the PIM tool.
In this study, we used the PIM tool to focus on the cardiovascular medication use, which represents one of the most commonly used medication groups in the population over 65 years old. 21 Additionally, other studies described the cardiovascular PIM criterion as one of the most frequently occurring PIMs. 20, [22] [23] [24] [25] Potential misuse of the cardiovascular medications can cause exacerbation of the cardiovascular diseases, adverse effects or cause cardiovascular diseases in predisposed patients, and increase the risk of mortality and hospitalisation. 26, 27 On the other hand, some cardiovascular medications, such as β-blockers, have known beneficial effects on morbidity and mortality in the treatment of the cardiovascular diseases, and their underuse may lead to increased risk of mortality and hospitalisation. [28] [29] [30] Few studies have explored the feasibility of electronic assessments of PIM criteria 5, 31 in field research databases or in primary care database from general practices. And a number of studies examined the association of high medication and PIM use with hospitalisation and mortality. 5, 20, 22, 32 The first aim of this study was to explore the feasibility of an electronic assessment of PIM criteria in a large administrative database enriched with clinical information in an older population in Stockholm County, Sweden. The second aim was to explore the associations of the number of medications and cardiovascular PIM use, with different clinical outcome such as mortality, unplanned hospitalisation and emergency department (ED) visit.
| METHODS

| Design
We conducted a cohort study using data derived from a comprehensive regional healthcare administrative database. We used data from 2015 for inclusion and medication use, and data from 2016 for outcome measures.
| Database characteristics
This study used Swedish data from the region of greater Stockholm (Stockholm County), covering all the 2.1 million inhabitants. 33 The administrative health data register of this region (Vårdanalysdatabasen, VAL; Stockholm regional healthcare data warehouse) contains all consultations in primary care and secondary care (defined as specialist outpatient care) and all hospitalisations and ED visits. VAL database contains demographic information on patient age, sex, migration and death, and it has been used in a number of previous studies. 24, [34] [35] [36] [37] Information on prescription drugs dispensed in the ambulatory setting is also included, through a link with the "Swedish Prescribed Drug Register" with a population coverage of over 99%. 38 The Anatomical Therapeutic Chemical [ATC] classification system was used to code dispensed drugs (version 2015). 39 
| Study population and study period
Patients eligible for inclusion were ≥65 years old, living in Stockholm County on the index date, 31 December 2015. This study focused on community residents, excluding all those residing in nursing homes. To minimise the risk of missing data, all people either moving in and out of the region during the whole study period (1 July 2015 to 31 December 2016) or being hospitalised during 2015 for more than 90 days were excluded.
| Data collection
| Collection of medication data
The total number of chronic medications dispensed on 31 December 2015 was included. In the Swedish pharmaceutical reimbursement system, each prescription is valid for 3 months. Therefore, we calculated the number of chronic medications during a 6-month period before the index date as "number of different medications dispensed at least twice during 1 July 2015 to 31 December 2015". 40 Cardiovascular chronic medication was defined as medication pertaining only to the first-level ATC C group. Polypharmacy was defined as concurrent use of five or more different chronic medications. Excessive polypharmacy was defined as concurrent use of ≥10 chronic medications. 3 
| Collection of clinical data
We collected information about the diagnoses needed for the application of the cardiovascular PIM criteria during the last 5 years before the index date. We collected the first recorded diagnosis in the period of 5 years, and from that moment, we considered that the resident had that diagnosis, a procedure also used in other studies on the VAL databases to identify chronic diseases. 25, 41 Identification of the clinical diagnosis needed for the application of the PIM criteria was made using ICD-10 classification for ischaemic heart disease (I20-I25), heart failure (I50) and hypertension (I10-15).
Comorbidity was defined as at least one occurrence of the diagnoses included in the Charlson Index, 42 in the last 5 years before the index date. Cut-off of ≥6 for the Charlson score was set to identify patients at high risk of mortality. 43 As hypertension is not part of the Charlson score, we decided to add hypertension as a separate covariate to the regression models, because we are comparing residents with cardiovascular disease to residents without cardiovascular disease, and we wanted to correct the results additionally for hypertension.
| Collection of outcome data
Outcome data were collected in the follow-up period from 1 January 2016 to 31 December 2016. During this one-year period, we collected data on mortality (yes or no), unplanned hospitalisation (at least one) and emergency department (ED) visit (at least one) during 2016. In the VAL database, unplanned hospitalisation is defined as every hospitalisation that is not booked at least one day before the hospitalisation date.
| Selecting cardiovascular explicit criteria
We included cardiovascular PIM criteria from the European Repository of PIM criteria. 15 The criteria were divided into two main groups, potentially inappropriate use or potential misuse further referred as misuse and potential underuse, further referred as underuse. In the further text, we will refer to them as misuse and underuse. Misuse was defined as the use of active substance in a manner not consistent with the medical guidelines. Underuse was defined as a failure to provide the medication when it is likely to produce a favourable outcome. Cardiovascular PIM criterion was defined as a criterion referring to a medication from the first-level ATC C group. Criteria referring to medications that were not registered in Sweden, or medications that were not prescribed to the study population, were excluded.
Criteria requesting information that is not available in the VAL database, such as history of disease, indication for the medication and laboratory results, were excluded. Criteria were also excluded if they required clinical information that was too specific and impossible to implement in electronic assessment (eg beta-blocker with symptomatic bradycardia [<50/min], type II heart block or complete heart block [risk of profound hypotension, asystole]).
Criteria that were mentioned in more than one list or criteria with the same medication but different clinical information requested were scrutinised for duplication. To avoid overestimation of PIM use, when there were clusters of two or more criteria addressing the same problem, we chose to apply only one criterion from the cluster, namely the one with clinical information applicable to our database. For example, the medication verapamil was present in all three lists. The criterion regarding verapamil from the STOPP (2014) list (verapamil or diltiazem with NYHA Class III or IV heart failure [may worsen heart failure]) requested too specific clinical information, not available in the VAL database. Both criteria, regarding verapamil from the EU-7 PIM list (verapamil) and Beers list (2015) (verapamil with heart failure), were applicable to the VAL database. To avoid overestimation of PIM use, we applied only one of these criteria. We chose to apply the criterion originating from the Beers list (2015), because this was a criterion requesting clinical information best tuned to the VAL database.
| Statistical analysis
SPSS 21.0 (Statistical Package for Social Sciences, SPSS Inc., Chicago, IL, USA) was used to perform the analysis.
Descriptive statistics was used, and data were presented as mean values and ranges. Categorical data were expressed using numbers and percentages. The number of medications was divided into three categories: no or low (0-4 medications), polypharmacy (5-9 medications) and excessive polypharmacy (≥10 medications). Misuse was divided into three categories: no (0 PIM), only 1 PIM and more than 1 PIM. Means and percentages were compared with chi-square test.
Multivariate logistic regression was used to calculate the odds ratios for associations with the outcome (mortality, unplanned hospitalisation and ED visits). Firstly, we used the above-described categories of the number of medications to explore the associations with the outcome. Secondly, we tested the associations of underuse and misuse expressed as continuous variables. Thirdly, we used the above-described categories of misuse to explore the associations with possible trends in higher mortality and hospitalisation rates, for higher categories misuse.
Possible covariates were age, gender, number of medications, Charlson score and hypertension. The results were corrected for the covariates which were significant in the univariate model. In the multivariate models, age, number of medications, and Charlson score were used as continuous variables.
A significance level was set at P < 0.05.
| Ethical approval
An ethical approval for the study protocol was obtained from the Ethical committee of Karolinska Institutet, Stockholm, Sweden (EC-number 2011/2080-31 and 2011/2080-31/5).
| RESULTS
A total of 353 266 residents aged ≥65 years, alive on the index date in Stockholm County, were identified. From those, 19 576 were excluded because they moved during the study period (1 July 2015 to 31 December 2016), 18 177 because they were admitted in a nursing home and 392 because they were hospitalised more than 90 days in 2015, resulting in a total study population of 315,120 participants ( Figure 1 ). The demographic and clinical characteristics of the population are shown in Table 1 . The mean age was 74.0 years (range 65-114), and 54.7% were women. Hypertension (52.9%), diabetes (20.0%), cancer (14.3%) and COPD (14.1%) were the most prevalent clinical conditions. Mean Charlson score was 1.9 (range (0-16), and 7.2% of the residents had a Charlson score ≥6. During 2015, the hospitalisation rate was 17.1%.
From the total population, 76.8% used chronic medications, and 42.8% used at least one medication pertaining to the first-level ATC C group of medications. Polypharmacy (≥5 medications) was present in 25.5% of the population (Table 2 ).
| Selection of cardiovascular PIM criteria
From the total number of 650 PIM criteria contained in the PIM repository, 15 111 criteria pertained to the cardiovascular PIM criteria.
Forty-four criteria were excluded because the active substance was not registered in Sweden (n = 23) or was not prescribed in the population (n = 21). From the remaining 67 criteria, an additional 31 criteria were excluded because information requested was not available in the database (n = 17 because requested information about indication, history of disease or laboratory results, and n = 14 because the criteria requested too specific diagnosis); and 12 criteria because of duplication ( Figure 2 , Table S1 for more details).
Thus, a total of 24 PIM criteria from the first-level ATC C group were applicable on the VAL database, from which 17 criteria originated from the EU(7)-PIM list, three criteria from the Beers list, two criteria from both EU(7)-PIM list and Beers list (2015), and two criteria from STOPP/START (2014) list. Only one applicable PIM criterion pertained to underuse (Table 3 ).
| Prevalence of cardiovascular PIM criterion
Cardiovascular PIM use was identified in 8.3% of the population, with a mean of 1.1 cardiovascular PIM per patient (range 1-4). Underuse only with one applicable criterion (beta-blocker with ischaemic heart disease) was identified in 2.8% of the population and misuse only in 5.3% of the population. Misuse and underuse together were present in 0.2% of the population. The combination of polypharmacy, misuse and underuse coexisted in 0.1% of the population (Table 4) .
The only applicable criterion for underuse was the absence of beta-blocker in the presence of ischaemic heart disease (3.0%). The most prevalent criterion for misuse was the intake of spironolactone (2.6%; Table 3 ).
3.3 | Univariate analysis of the association of the covariates, polypharmacy, underuse and misuse with the outcome Age, but not gender, showed a positive association with all three outcome, mortality, unplanned hospitalisation and ED visit. In residents with Charlson score ≥6 compared to those with Charlson score <6, the percentage of mortality, unplanned hospitalisation and ED visit was almost double as high. Polypharmacy was associated with a significant increase in all three outcome, especially with the ED visit. Underuse was associated with increased mortality (5.8% compared to 2.7% with no underuse), unplanned hospitalisation (26.3% compared to 14.6% with no underuse) and ED visit (40.9% compared to 21.6% with no underuse). Misuse was associated with increased mortality (5.4% compared to 2.6% with no misuse), unplanned hospitalisation (25.7% compared to 14.3% with no misuse) and ED visit (38.8% compared to 25.9% with no misuse; Table 5 ).
| Multivariate analysis for the impact of PIM use
The results of the multivariate analysis are shown in Table 6 . Mortality was significantly associated with the intake of ≥10 medications compared to no or low medication use (0-4 medications; OR 1.49, CI 95% 1.39-1.61) and with misuse expressed as a continuous variable (OR 1.09, CI 95% 1.02-1.17), after adjusting for all covariates.
Unplanned hospitalisation showed significant increase in residents with an intake of 5-9 medications (OR = 1.28, CI 1.24-1.31), and the risk was double in those with an intake of ≥10 medications (OR = 2.12, CI 2.03-2.21), compared to no or low medication use, after adjusting for all covariates. In relation to underuse and misuse, we observed an increased risk for the underused medication (OR = 1.12, CI 1.06-1.18), as well as increased risk for every additional misused medication (OR = 1.13, CI 1.09-1.18). Compared with no misuse, the OR for low misuse (1 PIM) was 1.13 (CI 1.08-1.18), and for high misuse (more than 1 PIM) OR = 1.32 (CI 1.14-1.52), for unplanned hospitalisation.
Emergency department visit, after adjusting for all covariates, was significant in residents with an intake of 5-9 medications (OR = 1.27, CI 1.24-1.30), and the risk was double in intake of ≥10 medications, compared to no or low medication use (OR = 2.09, CI 2.09-2.18). In relation to underuse and misuse, we observed an increased risk for the underused medication (OR = 1.25, CI 1.19-1.31), as well as an increased risk for every additional misused medication (OR = 1.12, CI 1.08-1.16). Compared with those with no misuse, the OR for low misuse (1 PIM) was 1.12 (CI 1.07-1.16), and for high misuse (more than 1 PIM) OR = 1.29 (CI 1.12-1.48).
| DISCUSSION
This is the first longitudinal cohort study performing electronic assessment of cardiovascular PIM use on an existing comprehensive regional administrative database. We covered a population of community-dwelling older adults by applying a cardiovascular subset from comprehensive lists of explicit PIM criteria, and we explored the associations of cardiovascular PIM use with mortality and hospitalisation.
| Main findings
We observed that 44 of the 111 cardiovascular PIM criteria contained in the repository of PIM criteria were not relevant for our Swedish population (not registered or not prescribed).
F I G U R E 1 Flow chart of the study population. *NH-nursing home
Of the 67 remaining, we had to exclude another 43 (requiring information not available in the database, or duplicates), resulting in 24 applicable criteria on potential underuse (n = 1) and on potential misuse (n = 23).
Even when focusing only on one medication group (the cardiovascular criteria) and even when not all criteria are applied, the prevalence of PIM use was high and it showed significant associations with relevant outcome.
| Methodological issues related to database specifications
By electronic selection, we were able to select the cardiovascular criteria, which represented 17% from the total criteria in the European Repository of PIM criteria. Although the VAL database is a large comprehensive database rich with clinical diagnoses, it does not include information such as indication of the medications, history of diseases and laboratory results. In addition, the clinical information sometimes is not recorded with sufficient granularity to use criteria based on very specific clinical information (eg heart failure with preserved systolic ventricular function) or data are not well recorded in the electronic health records (eg | 67 urinary incontinence, syncope). For this reason, the PIMs originating from the EU-7 PIM list were applied as medication name only PIMs or "first-order" PIMs. For example, the EU-7 PIM list for the most prevalent PIM "spironolactone" recommended periodical controls for all users above 65 years. Further, the list provides specific guidance for dose adjustments in patients with reduced kidney function. In this study, this PIM and all other PIMs originating from the EU-7 list were applied in broader sense, without assessing the specific subcriteria for a given PIM. Physicians with patients using spironolactone in patients over 65 years old can be invited to check the renal function. Another methodological issue related to the database specifications is the definition of chronic medications. Considering that in the Swedish pharmaceutical reimbursement system, each prescription is valid for no longer than 3 months; in this study, chronic medication use was defined as the number of different medications dispensed at least two times in the period of 6 months, and this definition was used in previous studies. 40 The definition of the chronic medication use in large administrative database varies between different countries and different systems. In Identification of the comorbidities was made using ICD-10 classification in primary care, with 5 years of prevalence, from 2010 to 2015 (ischaemic heart disease I20-I25, heart failure I50).
b
To apply this criterion, we used only heart failure ICD=10 I50 without the information about the severity of the disease. 
| Strengths and limitations
Firstly, the existence of the repository of PIM criteria and the application of the PIM tool represent a new approach of electronic assessment of (in)appropriate prescribing. We were able to electronically select a cardiovascular subset of explicit PIM criteria from different comprehensive PIM lists that match the specific focus of the research. In addition, we could select all criteria that were applicable for electronic assessment to our database. Secondly, we performed this electronic assessment of PIMs on a regional comprehensive administrative population database. This provides high power to identify associations with outcome, at lower cost than would be possible using clinical data at individual level, collected in field research. This approach can support efforts to improve the quality of pharmacotherapy in old age at population level. However, this method will never replace the benefits of multidisciplinary individual medication chart review. The results of this observational cohort study need to be interpreted with caution. Firstly, we applied only cardiovascular PIM criteria. Secondly, we did not use the full group of cardiovascular PIM criteria from the PIM repository, only those that were applicable in our database and suitable for the computerised evaluation. Even though the number of applied criteria was limited (n = 24), significant associations with relevant outcome were found. Also, other authors in previous studies made partial use of the PIM criteria for pragmatic reasons 5, 44 and the criteria applied in this study matched with the most prevalent cardiovascular PIM criteria in other studies. 22, 45 Due to the limitations of the database specifications and the limitations originating from the electronic selection of the criteria, underuse was assessed with only one criterion. For example, in the PIM tool, the START criterion "Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, unless the patient's status is end-of-life or age is >85 years" was marked as a criterion requesting information about the history of disease. As in the VAL database, information about the history of disease is not available, this criterion was excluded, although the requested information might have been reconstructed. This is not a valid approach to base a firm conclusion on the associations with underuse. Thirdly, although we found significant associations with outcome, residual confounding cannot be excluded. Factors that we were not able to measure, such as smoking, obesity, prescriber intention, psychological disorders and diabetes (although covered by the Charlson score), can influence the outcome measures. However, we have to accept the limitations of database research. Fourthly, we did not apply the PIM criteria pertaining to the first-level ATC B group, which might be relevant for the cardiovascular PIM use (eg from START list: Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history of coronary, cerebral or peripheral vascular disease). Lastly, regional differences between urban and non-urban areas are inventible, and these results cannot be generalised on the communitydwelling older adults in whole Sweden. We included the whole Stockholm elderly community-dwelling population; thus, these results can be generalised on the communitydwelling older adults in the Stockholm area, and possibly some similar urban areas in western Europe.
| Comparison with existing literature
A recent study on a comparison of PIM use among eight European countries, including Sweden, performed on residents of nursing homes, reported similar rates of PIM use from the cardiac therapeutic group. 20 According to this study, the overall prevalence of PIM use from the cardiac therapeutic group was 7.9%, and separately in Sweden 9.5%. This prevalence is a little bit higher than our findings (8.3%), which is expected in a nursing home population. Similar to our findings, the associations with mortality were less strong than with hospitalisation. A study from the United States, investigating the hospitalisation risk and PIM use, using electronic records of patients receiving nursing care at home 22 cardiovascular PIM criteria were applied, in comparison with 24 in our study. Also, from the six criteria, three were not prescribed in our population (digoxin, guanabenz and methyldopa) and the other three were among the criteria with low frequency (guanfacine, disopyramide and nifedipine). Still, the study reported 13% increased risk of 30-day hospitalisation, and 19% increased risk of 30-day rehospitalisation associated with cardiovascular PIM use, similar to our findings. One should be cautious when comparing the results regarding the percentages of electronically applicable criteria reported in our study with those with other studies. First of all, we focused on one group of medications, which restricted the number of applicable criteria (n = 111). From the remaining criteria, some were not relevant because they were not registered or prescribed in the country (n = 44). Lastly, we used combination of three lists that resulted with double criteria which were excluded because of risk of overestimation (n = 12). From the remaining 55 relevant criteria, we were able electronically to apply 24 criteria for misuse and underuse, which represents 44% of all relevant criteria. Other studies have reported percentages of electronically applicable misuse criteria from 38% and 63%, and for underuse from 57% and 69%. 5, 31 Unlike our study, both of these studies used only the STOPP/START list. Similar to our findings, as main reasons for inapplicability, they listed lack of information about the severity of a condition and lack of clinical tests.
| Implications for policy
The electronic application of the repository of PIM criteria on population-wide administrative database offers a possibility to assess the impact of PIM use, not only on individual patient level but also on the healthcare system level. This kind of broad assessment can be used for benchmarking, public health management or it can be used to provide individual feedback to prescribers.
| Implications for research
The repository of PIM criteria represents a start of automatisation of the assessment of PIM use. Although the number of applicable criteria was limited in this study, because of the focus on the cardiovascular criteria and due to limitation in the data specifications, we still found significant associations with relevant clinical outcome. This approach could allow a validation of the results of small-field studies in large databases studies on a population level, and to promote single explicit criteria or subsets of criteria to the status of quality indicator. For the application of the criteria requesting clinical data, large administrative databases need to be enriched with clinically validated data. The application of these criteria requires precise identification and codification of the diseases. In future, collection of more semantically operable clinical data needs to be assured.
| CONCLUSION
It was feasible to select a subset of cardiovascular PIM criteria originating from different lists and to electronically apply this subset on a comprehensive administrative database. Additionally, by applying this subset of criteria addressing potentially inappropriate medication use, we found significant associations of the cardiovascular PIM use with relevant clinical outcome. Although underuse assessed with only one criterion showed even stronger associations, the limitations of the data specifications did not allow valid electronic assessment of underuse.
In the Swedish community-dwelling older population, associations with mortality were found for intake of ≥10 medications and misuse. Underuse and misuse were both associated with unplanned hospitalisation and ED visit.
